3-(5-Nitro-2-thienyl)-9-chloro-5-morpholin-4-yl[1,2,4]triazolo[4,3-c] quinazoline induces ROS-mitochondrial mediated death signaling and activation of p38 MAPK in murine L1210 leukemia cells

Neoplasma

Volumn 56, Issue 6, 2009, Pages 494-499

  Jantova, S ^a   Repicky, A ^a   Cipak, L ^b  

^a SLOVAK UNIVERSITY OF TECHNOLOGY   (Slovakia)

^b INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Apoptosis; Caspase; Leukemia; p38 MAPK; Quinazoline derivative; Reactive oxygen species

Indexed keywords

3 (5 NITRO 2 THIENYL) 9 CHLORO 5 MORPHOLIN 4 YL[1,2,4]TRIAZOLO[4,3 C]QUINAZOLINE; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; QUINAZOLINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE 1; UNCLASSIFIED DRUG; 3 (5 NITRO 2 THIENYL) 9 CHLORO 5 MORPHOLIN 4 YL(1,2,4)TRIAZOLO(4,3 C)QUINAZOLINE; 3-(5-NITRO-2-THIENYL)-9-CHLORO-5-MORPHOLIN-4-YL(1,2,4)TRIAZOLO(4,3-C)QUINAZOLINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; STRESS ACTIVATED PROTEIN KINASE; TRIAZOLE DERIVATIVE;

ANIMAL CELL; APOPTOSIS; ARTICLE; DRUG EFFECT; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; LEUKEMIA L 1210; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; ANIMAL; CHEMICAL STRUCTURE; METABOLISM; MITOCHONDRION; PATHOLOGY;

ANIMALS; APOPTOSIS; CASPASE 3; CYTOCHROMES C; ENZYME ACTIVATION; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LEUKEMIA L1210; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MITOCHONDRIA; MOLECULAR STRUCTURE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; POLY(ADP-RIBOSE) POLYMERASES; QUINAZOLINES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TRIAZOLES;

EID: 70449709685     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2009_06_494     Document Type: Article

References (34)

1. CAI SX, DREWE J, KASIBHATLA S. A chemical genetics approach for the discovery of apoptosis inducers: from phenotypical cell based HTS assay and structure-activity relationship studies, to identification of potential anticancer agents and molecular targets. Curr Med Chem 2006; 13: 2627-2644. doi:10.2174/092986706778201521
2. BREMER E, VAN DAM G, KROESEN BJ, DE LEIJ L et al. Targeted introduction of apoptosis for cancer therapy: current progress and prospects.Trends Mol Med 2006; 12: 82-393. doi:10.1016/j.molmed.2006.06.002
3. PHILCHENKOV A, ZAVELEVICH M, KROSZAK TJ et al. Caspases and cancer: mechanisms of inactivation and new treatment modalities. Exp Oncol 2004; 26: 82-97. (Pubitemid 38981245)
4. COBB MH. MAP kinase pathways. Prog Biophys Mol Biol 1999; 71: 479-500. doi:10.1016/S0079-6107(98)00056-X
5. FUJISAWA T, TAKEDA K, ICHIJO H. ASK family proteins in stress response and disease. Mol Biotechnol 2007; 37: 13-28. doi:10.1007/s12033-007-0053-x
6. ABDEL-RAHMAN TM. Synthesis of some new biologically active 2,3-disubstituted quinazolin-4-ones. Boll Chim Farm 1998; 137: 43-47. (Pubitemid 128497426)
7. FARGHALY AM, CHAABAN I, KHALIL MA et al. Non-steroidal antiinflammatory agents. Synthesis of novel 2-pyrazolyl-4(3)-quinazolinones. Arch Pharmacol 1990; 323: 833-836. doi:10.1002/ardp.19903231004
8. POMARNACKA E, ANGIELSKI S, HOPPE A. Derivatives of 4-chloro-5-sulfanoyl- benzoic acid. 8. Synthesis and diuretic activity of pyrazole[3,2-b]quinazoline and 1-benzoylpyrazole derivatives. Acta Polon Pharm 1984; 41: 141-151.
9. KORNET MJ. Synthesis and anticonvulsant activity of 3-alkyl-3,4-dihydro- 2(1H)- quinazolinones. J Heterocyclic Chem 1992; 29: 103-105. doi:10.1002/jhet.5570290117
10. SHIMOYAMA M, OGINO K, TANAKA et al. Hemodynamic basic for the acute cardiac effects of troglitazone in isolated perfused rat hearts. Diabetes 1999; 3: 609-615. doi:10.2337/diabetes.48.3.609
11. SORENSON CM, BARRY MA, EASTMAN A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 1990; 82: 749-754. doi:10.1093/jnci/82.9.749
12. NAITHANI PK, PALIT G, SRIVASTAVA VK et al. 2,3-disubstituted quinazolinones and their antiparkinsonian activity. Ind J Chem Sect B Org Chem Incl Med Chem 1989; 28: 745-750.
13. LORIGA M, VITALE G, PAGLIETTI G. Quinoxaline chemistry. Part 9. Quinoxaline analogues of trimetrexate (TMQ) and 10-propargyl-5,8-dideazafolic acid (CB3717)and its precursors. Synthesis and evaluation of in vitro anticancer activity. Farmaco 1998; 53: 139-149. doi:10.1016/S0014-827X(98)00002-0
14. SOTELO-MUNDO RR, CIESLA J, DZÍK JM et al. Crystal structures of rat thymidylate synthase inhibited by Tomudex, a potential anticancer drug. Biochemistry 1990; 38: 1087-1094. doi:10.1021/bi981881d
15. JANTOVÁ S, URBANČÍKOVÁ M, MALIAR T et al. Biological activity of some 4-anilinoquinazolines: cytotoxic, genotoxic and antiprotease effects, induction of necrosis and changes of actin cytoskeleton. Neoplasma 2001; 1: 52-60.
16. RANSON M. Epidermal growth factor receptor tyrosine kinase inhibitors. Br J Cancer 2004; 90: 2250-2255. (Pubitemid 38961885)
17. KAYE SB. New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer 1998; 78: 1-7.
18. SZTANKE K, TUZIMSKI T, RZYMOWSKA J et al. Synthesis, determination of lipophilicity, anticancer and antimicrobial properties of some fused 1,2,4-triazole derivatives. Eur J Med Chem 2008; 43: 404-419. doi:10.1016/j.ejmech.2007.03.033
19. ŠPIRKOVÁ K, STANKOVSKÝ S. Amidinoyl isothiocyanates in the synthesis of condensed quinazolines. Preparation of 3-aryl-5,9- disubstituted s-triazolo[4,3-c]quinazolines. Collect Czech Chem Commun 1991; 56: 1719-1724.
20. ŠPIRKOVÁ K, STANKOVSKÝ S, HORNAČEK J. Amidinoyl isothiocyanates in the synthesis of condensed quinazolines. Preparation of 3-aryl-5,9-disubstituted s-triazolo[4,3-c]quinazolines and their [1,5-c]isomers. Chem Paper 1993; 6: 382-385.
21. JANTOVÁ S, THEISZOVÁ M, MIKULÁŠOVÁ M. Cytotoxic and genotoxic effects of some substituted tetrazolo[1,5-c] quinazolines. Neoplasma 2004; 51: 436-441.
22. JANTOVÁ S, OVÁDEKOVÁ R, LETAŠIOVÁ S et al. Antimicrobial activity of some substituted triazoloquinazolines. Folia Moicrobiol 2005; 50: 90-94. doi:10.1007/BF02931453
23. JANTOVÁ S, LETAŠIOVÁ S, REPICKÝ A et al. The effect of 3-(5-nitro- 2-thienyl)-9-chloro-5-morpholin-4-yl[1,2,4]triazolo[4,3-c] quinazoline on cell growth, cell cycle, induction of DNA fragmentation, and activity of caspase 3 in murine leukemia L1210 cells and fibroblast NIH-3T3 cells. Cell Biochem Funct 2006; 24: 519-530. doi:10.1002/cbf.1296
24. LOWRY OH, ROSEBROUGH NJ, FARR AL et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 143: 265.
25. VRABLIC AS, ALBRIGHT CD, CRACIUNESCU CN et al. Altered mitochondrial function and overgeneration of reactive oxygen species precede the induction of apoptosis by 1-O-octadecyl-2-methyl-rac-glycero-3-phosphocholine in p53-defective hepatocytes. FASEB J 2001; 15: 1739-1744. doi:10.1096/fj.00- 0300com
26. COHEN GM. Caspase, the executioners of apoptosis. Biochem J 1997; 326: 1-16.
27. REED JC. Cytochrome c can't live with it - can't live without it. Cell 1997; 91: 559-562.
28. KROEMER G. Mitochondrial control of apoptosis: an introduction. Biochem Biophys Res Commun 2003; 304: 433-443. doi:10.1016/S0006-291X(03)00614-4
29. CRAGG MS, KURODA J, PUTHALAKATH H et al. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 2007; 4: 1681-1689.
30. DENG J, SHIMAMURA T, PERERA S et al. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res 2007; 67: 11867-11875. doi:10.1158/0008-5472.CAN-07-1961
31. ARIAMA H, QIN B, BABA E et al. Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells. J Cell Biochem 2006; 97: 724-734 doi:10.1002/jcb.20678
32. ČIPÁK L, REPICKÝ A, Jantová S. Growth inhibition and apoptosis induced by 2-phenoxymethyl-3H-quinazolin-4-one in HL-60 leukemia cells. Exp Oncol 2007; 29: 13-17. (Pubitemid 46713473)
33. PARK SJ, KIM IS. The role of p38 MAPK activation in auranofin-induced apoptosis of human promyelocytic leukaemia HL-60 cells. Br J Pharm 2005; 146: 506-513. doi:10.1038/sj.bjp.0706360
34. KURAT S. Selective activation of p38 MAPK cascade and mitotic arrest cause by low level oxidative stress. J Biol Chem 2000; 31: 23413-23416. doi:10.1074/jbc.C000308200